Trina Greenwald
Psychiatric/Mental Health · Marion, INNPI 1548298409
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,103 of the $107,382 with a category attached, or 63.4%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 62.1% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $44,822, more than ten times the $3,072 reported in 2021. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 767 payments — averaging $140.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$67K
- AbbVie$21K
- Axsome Therapeutics, Inc.$13K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$996
- Corium, LLC$596
- plus $4K from 22 others
What the payments were for
- Consulting fees$7,3937%
- Speaking & faculty fees$68,10363%
- Travel & lodging$20,62219%
- Food & beverage$11,15610%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 155 | $66,738 |
| AbbVie | 141 | $20,916 |
| Axsome Therapeutics, Inc. | 42 | $13,229 |
| Lundbeck LLC | 96 | $1,092 |
| Otsuka America Pharmaceutical, Inc. | 64 | $996 |
| Corium, LLC | 47 | $596 |
| Vanda Pharmaceuticals Inc. | 29 | $512 |
| Neurocrine Biosciences, Inc. | 32 | $457 |
| Supernus Pharmaceuticals, Inc. | 26 | $436 |
| Tris Pharma Inc | 17 | $428 |
| Teva Pharmaceuticals USA, Inc. | 14 | $355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $222 |
| Sunovion Pharmaceuticals Inc. | 17 | $196 |
| E.r. Squibb & Sons, L.L.C. | 16 | $192 |
| Alkermes, Inc. | 9 | $175 |
| Johnson & Johnson | 8 | $133 |
| Adlon Therapeutics L.p. | 7 | $124 |
| Avanir Pharmaceuticals, Inc. | 6 | $110 |
| Noven Therapeutics, LLC | 6 | $98 |
| Idorsia Pharmaceuticals US Inc | 5 | $82 |
| Merck | 4 | $58 |
| Acadia Pharmaceuticals Inc | 3 | $55 |
| Novo Nordisk | 3 | $50 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Eisai Inc. | 3 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$64,627
- VRAYLAR$18,970
- Auvelity$12,503
- AUSTEDO$125
- ABILIFY MAINTENA$117
How this compares
$107,382 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 96 | $833,971 |
| FanaptIloperidone | 187 | $296,318 |
| VraylarCariprazine Hcl | 144 | $238,733 |
| CaplytaLumateperone Tosylate | 117 | $200,150 |
| Austedo XrDeutetrabenazine | 26 | $180,665 |
| RexultiBrexpiprazole | 87 | $172,264 |
| NuedextaDextromethorphan Hbr/Quinidine | 77 | $144,643 |
| TrintellixVortioxetine Hydrobromide | 182 | $140,590 |
| AuvelityDextromethorphan Hbr/Bupropion | 112 | $129,682 |
| NuplazidPimavanserin Tartrate | 20 | $101,915 |
| AustedoDeutetrabenazine | 15 | $86,494 |
| OzempicSemaglutide | 45 | $70,003 |
| Abilify MaintenaAripiprazole | 23 | $64,540 |
| BelsomraSuvorexant | 66 | $46,197 |
| SpravatoEsketamine Hcl | 37 | $37,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $457 | $833,97196 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $512 | $296,318187 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $355 | $267,15941 claims |
| AbbVieVraylar, Fetzima | $20,916 | $259,574170 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $996 | $236,805110 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $66,738 | $200,150117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $222 | $172,090228 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $110 | $144,64377 claims |
| Axsome Therapeutics, Inc.Auvelity | $13,229 | $129,682112 claims |
| Acadia Pharmaceuticals IncNuplazid | $55 | $101,91520 claims |
| Novo NordiskOzempic, Wegovy | $50 | $84,60256 claims |
| MerckBelsomra | $58 | $46,19766 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Marion
- Annalise MichaudMarion$9K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.